DRI HEALTHCARE TRUST (DHT-U.CA) Stock Price, Forecast & Analysis
Canada - TSX:DHT-U - CA23344H1091
11.3 USD
+0.59 (+5.51%)
Taking everything into account, DHT-U scores 5 out of 10 in our fundamental rating. DHT-U was compared to 32 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of DHT-U get a neutral evaluation. Nothing too spectacular is happening here. DHT-U is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year DHT-U was profitable.
DHT-U had a positive operating cash flow in the past year.
1.2 Ratios
With a decent Return On Assets value of 0.41%, DHT-U is doing good in the industry, outperforming 71.88% of the companies in the same industry.
The Return On Equity of DHT-U (0.78%) is better than 71.88% of its industry peers.
DHT-U has a better Return On Invested Capital (3.82%) than 68.75% of its industry peers.
DHT-U had an Average Return On Invested Capital over the past 3 years of 1.94%. This is significantly below the industry average of 7.63%.
The last Return On Invested Capital (3.82%) for DHT-U is above the 3 year average (1.94%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.41% | ||
| ROE | 0.78% | ||
| ROIC | 3.82% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of DHT-U (2.11%) is better than 75.00% of its industry peers.
The Operating Margin of DHT-U (25.45%) is better than 90.63% of its industry peers.
In the last couple of years the Operating Margin of DHT-U has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.45% | ||
| PM (TTM) | 2.11% | ||
| GM | N/A |
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DHT-U has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
DHT-U has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, DHT-U has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.18, we must say that DHT-U is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.18, DHT-U is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
DHT-U has a debt to FCF ratio of 3.05. This is a good value and a sign of high solvency as DHT-U would need 3.05 years to pay back of all of its debts.
DHT-U has a Debt to FCF ratio of 3.05. This is amongst the best in the industry. DHT-U outperforms 90.63% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that DHT-U is somewhat dependend on debt financing.
DHT-U has a Debt to Equity ratio of 0.77. This is in the lower half of the industry: DHT-U underperforms 71.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 3.05 | ||
| Altman-Z | 1.18 |
ROIC/WACC0.5
WACC7.59%
2.3 Liquidity
DHT-U has a Current Ratio of 1.83. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.83, DHT-U perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
DHT-U has a Quick Ratio of 1.83. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
DHT-U has a Quick ratio of 1.83. This is in the better half of the industry: DHT-U outperforms 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
The earnings per share for DHT-U have decreased strongly by -11.89% in the last year.
DHT-U shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.09% yearly.
DHT-U shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.24%.
DHT-U shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.25% yearly.
EPS 1Y (TTM)-11.89%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%4.08%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%6.07%
3.2 Future
DHT-U is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.64% yearly.
Based on estimates for the next years, DHT-U will show a quite strong growth in Revenue. The Revenue will grow by 9.41% on average per year.
EPS Next Y-4.59%
EPS Next 2Y3.65%
EPS Next 3Y6.08%
EPS Next 5Y10.64%
Revenue Next Year10.56%
Revenue Next 2Y5.58%
Revenue Next 3Y3.77%
Revenue Next 5Y9.41%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.26, the valuation of DHT-U can be described as very cheap.
DHT-U's Price/Earnings ratio is rather cheap when compared to the industry. DHT-U is cheaper than 93.75% of the companies in the same industry.
DHT-U's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.56.
A Price/Forward Earnings ratio of 4.85 indicates a rather cheap valuation of DHT-U.
Based on the Price/Forward Earnings ratio, DHT-U is valued cheaper than 93.75% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of DHT-U to the average of the S&P500 Index (34.62), we can say DHT-U is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.26 | ||
| Fwd PE | 4.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DHT-U is valued cheaper than 87.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, DHT-U is valued cheaply inside the industry as 84.38% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.27 | ||
| EV/EBITDA | 6.62 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.65%
EPS Next 3Y6.08%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.57%, DHT-U is a good candidate for dividend investing.
DHT-U's Dividend Yield is rather good when compared to the industry average which is at 3.64. DHT-U pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, DHT-U pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
5.2 History
DHT-U has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y3.65%
EPS Next 3Y6.08%
TSX:DHT-U (11/14/2025, 7:00:00 PM)
11.3
+0.59 (+5.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners56.4%
Inst Owner ChangeN/A
Ins Owners0.89%
Ins Owner ChangeN/A
Market Cap623.65M
Revenue(TTM)186.77M
Net Income(TTM)3.93M
Analysts80
Price Target14.57 (28.94%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.16%
Min EPS beat(2)-21.52%
Max EPS beat(2)5.2%
EPS beat(4)3
Avg EPS beat(4)6.36%
Min EPS beat(4)-21.52%
Max EPS beat(4)39.35%
EPS beat(8)5
Avg EPS beat(8)18.78%
EPS beat(12)7
Avg EPS beat(12)90.93%
EPS beat(16)8
Avg EPS beat(16)66.47%
Revenue beat(2)0
Avg Revenue beat(2)-0.5%
Min Revenue beat(2)-0.64%
Max Revenue beat(2)-0.37%
Revenue beat(4)2
Avg Revenue beat(4)14.3%
Min Revenue beat(4)-0.64%
Max Revenue beat(4)46.19%
Revenue beat(8)5
Avg Revenue beat(8)27.34%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.35%
EPS NQ rev (3m)18.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.26 | ||
| Fwd PE | 4.85 | ||
| P/S | 3.34 | ||
| P/FCF | 4.27 | ||
| P/OCF | 4.27 | ||
| P/B | 1.24 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.62 |
EPS(TTM)2.15
EY19.03%
EPS(NY)2.33
Fwd EY20.63%
FCF(TTM)2.65
FCFY23.44%
OCF(TTM)2.65
OCFY23.44%
SpS3.38
BVpS9.12
TBVpS-4.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.41% | ||
| ROE | 0.78% | ||
| ROCE | 5.31% | ||
| ROIC | 3.82% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 90.74% | ||
| OM | 25.45% | ||
| PM (TTM) | 2.11% | ||
| GM | N/A | ||
| FCFM | 78.26% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
ROICexc(3y)2.05%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.74%
ROCE(5y)N/A
ROICexgc growth 3Y44.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.25%
ROICexc growth 5YN/A
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 3.05 | ||
| Debt/EBITDA | 2.61 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.99% | ||
| Profit Quality | 3716.37% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 1.18 |
F-Score6
WACC7.59%
ROIC/WACC0.5
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.89%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%4.08%
EPS Next Y-4.59%
EPS Next 2Y3.65%
EPS Next 3Y6.08%
EPS Next 5Y10.64%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%6.07%
Revenue Next Year10.56%
Revenue Next 2Y5.58%
Revenue Next 3Y3.77%
Revenue Next 5Y9.41%
EBIT growth 1Y343.32%
EBIT growth 3Y24.15%
EBIT growth 5YN/A
EBIT Next Year104.78%
EBIT Next 3Y26.53%
EBIT Next 5Y23.58%
FCF growth 1Y103.46%
FCF growth 3Y19.16%
FCF growth 5YN/A
OCF growth 1Y103.46%
OCF growth 3Y19.16%
OCF growth 5YN/A
DRI HEALTHCARE TRUST / DHT-U.CA FAQ
What does DHT-U do?
DRI Healthcare Trust is an unincorporated open-ended company. The company is headquartered in Toronto, Ontario and currently employs 36 full-time employees. The company went IPO on 2021-02-11. The firm provides capital to universities and research institutions, academic institutions, biotechnology companies and pharmaceutical companies. The company acquires more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, and other products. Its therapeutic areas include oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (LSD) and immunology. The firm is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Galderma, and others.
What is the current price of DHT-U stock?
The current stock price of DHT-U.CA is 11.3 USD. The price increased by 5.51% in the last trading session.
How is the ChartMill rating for DRI HEALTHCARE TRUST?
DHT-U.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.